ESR1 and breast carcinoma: For miR-375, its downregulation suppresses epithelial-to-mesenchymal transition in invasive basal-like tumor cells and its upregulation augments cellular proliferation in ERα+ breast cancer cells through a positive feedback loop [104–107].